Press Release

Data demonstrates the potential of ‘1104 as an allergen-agnostic therapeutic for the treatment of food allergy NEW ORLEANS, LA and CAMBRIDGE, England, February 28, 2023 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today […]

NEW ORLEANS and LONDON, February 6, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy

NEW ORLEANS, LA and LONDON, UK, November 14, 2022 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the TIDES Europe 2022 Conference on Oligonucleotide & Peptide Therapeutics,

Topline data anticipated in early 2023 NEW ORLEANS, LA and LONDON, UK, November 9, 2022 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the last patient has completed a Phase 2a proof

NEW ORLEANS, LA and LONDON, UK, November 2, 2022 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued US Patent No. 11,479,585 (“the ‘585 patent”)

NEW ORLEANS, LA and LONDON, UK, September 16, 2022 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Sachs Associates 22nd Annual Biotech in Europe Forum for

Topline data anticipated around year-end 2022 NEW ORLEANS, LA and LONDON, UK, September 12, 2022 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it has completed enrollment and has fully randomized all

NEW ORLEANS, LA and LONDON, UK, September 8, 2022 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it will be participating in the Baird 2022 Global Healthcare Conference being held in New

NEW ORLEANS, LA and LONDON, UK, July 14, 2022 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that it was awarded an Innovative Medicines Designation, or Innovation Passport, from the Medicines and

Presenting new data on ‘1104 in allergic disease at the American Thoracic Society International Conference in San Francisco on May 17 Delivering an oral presentation on resetting the immune system to achieve long-term disease remission at the Treg Summit in Boston on May 19 NEW ORLEANS, LA and LONDON, UK, May 16, 2022 – Revolo